[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL1767546T3 - Hamujące angiogenezę białka chimeryczne i ich zastosowanie - Google Patents

Hamujące angiogenezę białka chimeryczne i ich zastosowanie

Info

Publication number
PL1767546T3
PL1767546T3 PL05752254T PL05752254T PL1767546T3 PL 1767546 T3 PL1767546 T3 PL 1767546T3 PL 05752254 T PL05752254 T PL 05752254T PL 05752254 T PL05752254 T PL 05752254T PL 1767546 T3 PL1767546 T3 PL 1767546T3
Authority
PL
Poland
Prior art keywords
chimeric protein
angiogenesis
inhibiting
inhibiting chimeric
protein
Prior art date
Application number
PL05752254T
Other languages
English (en)
Inventor
Zheng Liu
Original Assignee
Chengdu Kanghong Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologies Co Ltd filed Critical Chengdu Kanghong Biotechnologies Co Ltd
Publication of PL1767546T3 publication Critical patent/PL1767546T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
PL05752254T 2004-06-08 2005-06-08 Hamujące angiogenezę białka chimeryczne i ich zastosowanie PL1767546T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410044965 2004-06-08
EP05752254A EP1767546B1 (en) 2004-06-08 2005-06-08 Angiogenesis-inhibiting chimeric protein and the use
PCT/CN2005/000802 WO2005121176A1 (fr) 2004-06-08 2005-06-08 Proteine chimerique inhibitrice d'angiogenese et utilisation associee

Publications (1)

Publication Number Publication Date
PL1767546T3 true PL1767546T3 (pl) 2012-07-31

Family

ID=35503012

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05752254T PL1767546T3 (pl) 2004-06-08 2005-06-08 Hamujące angiogenezę białka chimeryczne i ich zastosowanie

Country Status (13)

Country Link
US (2) US7750138B2 (pl)
EP (1) EP1767546B1 (pl)
JP (1) JP4680997B2 (pl)
KR (1) KR100897379B1 (pl)
AT (1) ATE548384T1 (pl)
BR (1) BRPI0512286B8 (pl)
CA (1) CA2569108C (pl)
DK (1) DK1767546T3 (pl)
ES (1) ES2381014T3 (pl)
PL (1) PL1767546T3 (pl)
PT (1) PT1767546E (pl)
RU (1) RU2355414C2 (pl)
WO (1) WO2005121176A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027096T2 (en) 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
EP3753548A1 (en) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
KR20240110092A (ko) 2011-01-13 2024-07-12 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
SI3536310T1 (sl) 2012-06-01 2021-08-31 Novartis Ag Brizga
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
DE202012011016U1 (de) 2012-07-03 2012-11-28 Novartis Ag Aflibercept-Spritze
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP3010542A1 (en) 2013-06-20 2016-04-27 Novartis AG Treatment of polypoidal choroidal vasculopathy
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
JP2016522250A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
CN105377891A (zh) 2013-07-11 2016-03-02 诺华股份有限公司 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
MX368442B (es) * 2014-01-25 2019-10-02 Chengdu Kanghong Biotechnologies Co Ltd Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017001990A1 (en) 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017148904A1 (en) 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
WO2018224644A1 (en) 2017-06-08 2018-12-13 Novartis Ag Injection device and injection solution transferring system
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
US20200148757A1 (en) * 2017-06-30 2020-05-14 Korea Advanced Institute Of Science And Technology Conjugate of vegf-grab protein and drug, and use thereof
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
US20220332792A1 (en) * 2019-09-04 2022-10-20 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN115335529A (zh) * 2019-11-26 2022-11-11 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
WO2021119544A1 (en) 2019-12-12 2021-06-17 Novartis Ag Injection device and injection solution transferring system
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20230061441A (ko) * 2020-09-03 2023-05-08 유니버시티 오브 매사추세츠 Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도
IL308505A (en) 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023177691A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
IL315347A (en) 2022-03-15 2024-11-01 Regeneron Pharmaceuticals Inc Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230542T3 (es) * 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
PT1183353E (pt) * 1999-06-08 2005-06-30 Regeneron Pharma Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
CN101134777A (zh) * 2006-08-31 2008-03-05 苏州思坦维生物技术有限责任公司 可拮抗血管内皮细胞生长因子的人源化的免疫球蛋白的制备方法及其组合应用

Also Published As

Publication number Publication date
JP2008503243A (ja) 2008-02-07
EP1767546A4 (en) 2008-03-19
BRPI0512286A (pt) 2008-03-18
DK1767546T3 (da) 2012-04-23
US20100215655A1 (en) 2010-08-26
BRPI0512286B8 (pt) 2021-05-25
EP1767546A1 (en) 2007-03-28
JP4680997B2 (ja) 2011-05-11
ATE548384T1 (de) 2012-03-15
US7750138B2 (en) 2010-07-06
KR100897379B1 (ko) 2009-05-14
KR20070029204A (ko) 2007-03-13
CA2569108A1 (en) 2005-12-22
RU2355414C2 (ru) 2009-05-20
EP1767546B1 (en) 2012-03-07
ES2381014T3 (es) 2012-05-22
BRPI0512286B1 (pt) 2020-03-24
PT1767546E (pt) 2012-03-20
RU2006146995A (ru) 2008-07-20
WO2005121176A1 (fr) 2005-12-22
CA2569108C (en) 2012-08-21
US20080206238A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
EP1767546A4 (en) AN ANGIOGENESIS INHIBITING CHIMERIC PROTEIN AND ITS USE
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
TW200505875A (en) Novel compounds
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
WO2008121615A3 (en) Antibody formulation
WO2004020595A3 (en) Novel human polypeptides encoded by polynucleotides
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
TW200407425A (en) Human coagulation factor VII polypeptides
WO2009081374A3 (en) Cosmetic use of plakoglobin-type proteins
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
EP2392655A3 (en) Coagulation factor VII polypeptides
WO2004093804A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2007045019A3 (en) Polyoleosins
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
ZA200700178B (en) Pharmaceutical composition containing polypeptide fragments of serralysins
WO2004020591A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2008014054A3 (en) Bmp-7 variant compositions, methods and uses
GB0409559D0 (en) Polypeptide
WO2007048100A3 (en) Angio-inhibitory peptides derived from human timp-2
WO2004094598A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
ITMI20041965A1 (it) "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici"
DE602004021922D1 (de) Induktion der blütenbildung